Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocytes (14 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 117 | 0.85 |
| pathways Reactome | 4 pathways; mostly lysosome and autophagy | 1.00 |
Knock down and overexpress RNF5 in oligodendrocytes; measure glucocerebrosidase (GCase) activity and LC3-II and p62 flux and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- glucocerebrosidase (GCase) activity and LC3-II and p62 flux
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves glucocerebrosidase (GCase) activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of RNF5 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: glucocerebrosidase (GCase) activity and LC3-II and p62 flux; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- RNF5 in dopamine neurons, braak+0.10 (p 0.803) → -0.27 (p 0.487)receipt 13361
- RNF5 in oligodendrocytes, braak+0.35 (p 0.361) → +0.06 (p 0.869)receipt 13360
Swarm cases
receipt 13361: RNF5 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.928, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.08, sign flips 4; without severely affected donors -0.04 (p 0.867, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF5 in dopamine neurons.
case closed: nothing better to follow up.
receipt 13360: RNF5 in oligodendrocytes, braak
- power
- full sample +0.27 (p 0.281, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.11 (p 0.658, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.11 (p 0.677, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.46, sign flips 0; without severely affected donors +0.27 (p 0.281, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF5 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts